secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2026-06-05T11:12:49+00:00
Accession:  0001193125-26-258372
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio reports positive Phase 1 safety data for CLYM116; plans Phase 2 in IgAN in Q3 2026
--------------------------------------------------------------------------------

- Translational PK/PD model from NHP data projects dose-dependent IgA suppression, suggesting less-frequent dosing.
- Preliminary safety from 49 healthy volunteers (single doses up to 320 mg): no SAEs, DLTs, or discontinuations; all AEs mild-moderate and transient.
- Partner Mabworks to initiate Phase 2 dosing in IgAN patients in Q3 2026 in China.
- Company plans to advance CLYM116 into further clinical development based on data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526258372/0001193125-26-258372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526258372/d132290d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-258372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer